StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Galectin Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Galectin Therapeutics's total assets was $14.83M at Jun 30, 2026. For fiscal 2025 it was $19.53M, up 11.6% from the year before. Over ten years it grew -3.0% a year on average. The highest annual figure on record is $48.47M in fiscal 2019.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.53M+11.6%
FY2024Dec 31, 2024$17.50M-38.0%
FY2023Dec 31, 2023$28.20M+32.5%
FY2022Dec 31, 2022$21.29M-49.1%
FY2021Dec 31, 2021$41.83M+41.3%
FY2020Dec 31, 2020$29.60M-38.9%
FY2019Dec 31, 2019$48.47M+438.2%
FY2018Dec 31, 2018$9.01M+116.4%
FY2017Dec 31, 2017$4.16M-73.7%
FY2016Dec 31, 2016$15.80M-40.2%
FY2015Dec 31, 2015$26.41M-11.0%
FY2014Dec 31, 2014$29.68M+177.0%
FY2013Dec 31, 2013$10.71M+12.0%
FY2012Dec 31, 2012$9.56M+44.6%
FY2011Dec 31, 2011$6.61M+5.0%
FY2010Dec 31, 2010$6.30M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.83M-5.0%
Q1 FY2026Mar 31, 2026$15.76M+65.4%
Q4 FY2025Dec 31, 2025$19.53M+11.6%
Q3 FY2025Sep 30, 2025$12.87M-55.6%
Q2 FY2025Jun 30, 2025$15.60M-43.6%
Q1 FY2025Mar 31, 2025$9.53M-63.2%
Q4 FY2024Dec 31, 2024$17.50M-38.0%
Q3 FY2024Sep 30, 2024$28.97M+30.7%
Q2 FY2024Jun 30, 2024$27.66M+37.7%
Q1 FY2024Mar 31, 2024$25.89M+28.0%
Q4 FY2023Dec 31, 2023$28.20M+32.5%
Q3 FY2023Sep 30, 2023$22.16M+23.7%
Q2 FY2023Jun 30, 2023$20.08M-22.4%
Q1 FY2023Mar 31, 2023$20.23M-39.8%
Q4 FY2022Dec 31, 2022$21.29M-49.1%
Q3 FY2022Sep 30, 2022$17.91M-52.9%
Q2 FY2022Jun 30, 2022$25.89M-22.5%
Q1 FY2022Mar 31, 2022$33.62M+46.8%
Q4 FY2021Dec 31, 2021$41.83M+41.3%
Q3 FY2021Sep 30, 2021$38.04M+11.7%
Q2 FY2021Jun 30, 2021$33.41M-19.1%
Q1 FY2021Mar 31, 2021$22.90M-48.1%
Q4 FY2020Dec 31, 2020$29.60M-38.9%
Q3 FY2020Sep 30, 2020$34.05M-32.9%
Q2 FY2020Jun 30, 2020$41.32M-22.1%
Q1 FY2020Mar 31, 2020$44.11M+463.4%
Q4 FY2019Dec 31, 2019$48.47M+438.2%
Q3 FY2019Sep 30, 2019$50.76M+378.1%
Q2 FY2019Jun 30, 2019$53.01M+372.9%
Q1 FY2019Mar 31, 2019$7.83M+58.8%
Q4 FY2018Dec 31, 2018$9.01M+116.4%
Q3 FY2018Sep 30, 2018$10.62M+51.4%
Q2 FY2018Jun 30, 2018$11.21M+20.2%
Q1 FY2018Mar 31, 2018$4.93M-64.8%
Q4 FY2017Dec 31, 2017$4.16M-73.7%
Q3 FY2017Sep 30, 2017$7.01M-56.5%
Q2 FY2017Jun 30, 2017$9.33M–
Q1 FY2017Mar 31, 2017$14.00M–
Q4 FY2016Dec 31, 2016$15.80M–
Q3 FY2016Sep 30, 2016$16.12M–

More Galectin Therapeutics figures

See a number that looks wrong?